Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Nycomed suspends development of anticlotting agent

Nov. 8, 1996

Cor Therapeutics' fibrinogen receptor antagonist effective in unstable angina

Nov. 8, 1996

Orally active antithrombotic RGD-mimetics reported by E. Merck

Nov. 8, 1996

Fujisawa claims fibrinogen antagonists

Nov. 8, 1996

Canadian researchers claim hirudin derivative

Nov. 8, 1996

Factor Xa/thrombin inhibitors from Roche

Nov. 1, 1996

Berlex discloses factor Xa inhibitors

Nov. 1, 1996

Transgenic ATIII proven safe in healthy volunteers

Oct. 25, 1996

Promising preliminary phase II results for argatroban in acute MI

Oct. 25, 1996

Servier selects TxA2 antagonist for further study

Oct. 18, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...